Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

14.77
+0.72005.12%
Pre-market: 14.790.0170+0.12%09:13 EDT
Volume:2.97M
Turnover:43.62M
Market Cap:1.39B
PE:-4.68
High:14.98
Open:13.88
Low:13.81
Close:14.05
52wk High:15.71
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:0.92
T/O Rate:3.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:13.17
PE(LYR):-4.37

Loading ...

Replimune Slips as FDA Accepts Skin Cancer Drug Review, but Advisory Panel Adds Risk

Reuters
·
Jun 26

Replimune Says FDA Accepts RP1 Melanoma BLA Resubmission for Review

Reuters
·
Jun 26

Replimune Group - FDA Sets August 2, 2026 Goal Date for Rp1 Bla Review

THOMSON REUTERS
·
Jun 26

Replimune Announces FDA Acceptance of Rp1 Biologics License Application Resubmission for Advanced Melanoma

THOMSON REUTERS
·
Jun 26

U.S. Earnings Preview: Before Market Open June 25

Dow Jones
·
Jun 25

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Replimune Group Inc expected to post a loss of 71 cents a share - Earnings Preview

Reuters
·
Jun 19

U.S. Earnings Preview: Before Market Open June 18

Dow Jones
·
Jun 18

U.S. Earnings Preview: Before Market Open June 11

Dow Jones
·
Jun 11

U.S. Earnings Preview: Before Market Open June 4

Dow Jones
·
Jun 04

Replimune Chief Commercial Officer Christopher Sarchi sells 12,000 shares for $110,880

Reuters
·
Jun 04

Replimune Group Is Maintained at Neutral by Wedbush

Dow Jones
·
Jun 01

Replimune Group trading halted, volatility trading pause

TIPRANKS
·
Jun 01

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM

Reuters
·
Jun 01

Replimune price target raised to $6 from $2 at Wedbush

TIPRANKS
·
Jun 01

Replimune Says Evaluating RP2 for Metastatic Uveal Melanoma in Phase 2/3 Trial; Shares Up Pre-Bell

MT Newswires Live
·
Jun 01

Replimune Group Inc : JP Morgan Raises to Neutral From Underweight

THOMSON REUTERS
·
Jun 01

Replimune presents final first-in-human data for RP2 alone, with nivolumab

TIPRANKS
·
Jun 01

Replimune presents 3-year overall survival data from IGNYTE trial

TIPRANKS
·
Jun 01

Replimune publishes RP2 Phase 1 ASCO presentation data###

Reuters
·
May 31